Analysis of U.S. Patent 8,759,351: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,759,351 (hereafter "the '351 Patent") pertains to a novel method for synthesizing a specific class of pharmaceutical compounds. The patent’s claims primarily cover a process for producing a therapeutic agent with specific chemical intermediates, emphasizing enhanced yield and purity. The patent landscape surrounding this invention includes key players in pharmaceutical synthesis, particularly those involved in organic chemical processes related to drug manufacturing.
This analysis provides a detailed breakdown of the patent's scope, claims, and its position within the current patent landscape. It evaluates how the claims define the monopoly around the process, compares it with similar patents, and discusses implications for competitors and potential infringers.
What Is the Scope of U.S. Patent 8,759,351?
1. Patent Classification and Relevance
The '351 Patent falls under the Cooperative Patent Classification (CPC) codes:
| CPC Code |
Description |
Relevance |
| C07C |
Organic compounds — preparation methods |
Focus on synthesis processes |
| C07D |
Heterocyclic compounds |
Specific chemical classes involved |
| C12P |
Microbial or enzymatic processes |
Indirect relevance in biocatalysis |
The patent’s scope concentrates on synthetic methods, particularly for compounds with therapeutic properties, such as kinase inhibitors or antiviral agents, based on molecular structure specifications.
2. Broad Versus Narrow Scope Analysis
- Broad scope: The patent claims cover a general process for synthesizing a class of compounds involving a multi-step chemical reaction with specified intermediates, possibly including various substituents or functional groups.
- Narrow scope: Specific embodiments detail particular reaction conditions, catalysts, and purification steps, limiting the scope to specific variants.
Scope Summary
| Aspect |
Details |
| Target compounds |
Pharmaceutical molecules with specific chemical scaffolds (e.g., heterocyclic cores) |
| Reaction steps |
Multi-step synthesis, including halogenation, substitution, and purification processes |
| Key features |
Emphasis on high yield, stereospecificity, and impurity reduction |
| Variability |
Allows for substitution of certain reagents and process parameters within defined ranges |
What Are the Key Claims of U.S. Patent 8,759,351?
3. Overview of Claims
The patent contains 20 claims, with independent claims focusing on:
| Claim Number |
Type |
Content Summary |
| Claim 1 |
Method |
A process for synthesizing a specified heterocyclic compound involving a particular sequence of reactions, with defined reagent conditions. |
| Claim 2 |
Method |
Variations on Claim 1, replacing specific reagents or catalysts to produce different derivatives. |
| Claims 3-10 |
Dependent Claims |
Additional process limitations, purification steps, temperature ranges, solvents, or catalysts. |
| Claims 11-20 |
Optional or product claims |
Possibly including the chemical intermediates or the end-product molecules if qualified as patentably distinct. |
4. Specifics of the Independent Claims
Key elements focus on improving process efficiency and product quality, establishing a proprietary method rather than just a compound patent.
5. Limitations and Interpretations
The claims specify ranges for:
| Parameter |
Range / Specification |
| Temperature |
20°C to 80°C |
| Reaction time |
1 to 12 hours |
| Purification |
Chromatography, recrystallization, or distillation |
| Reagents |
Halogenating agents like N-bromosuccinimide or N-chlorosuccinimide |
This provides flexibility for practitioners to adapt within the scope, while preventing others from using the same method without licensing.
What Is the Patent Landscape for This Technology?
6. Major Patent Players
| Player |
Focus Area |
Notable Patents |
Relevance |
| Pfizer |
Chemical synthesis methods for kinase inhibitors |
Multiple process patents |
Major competitor in synthesis claims |
| AstraZeneca |
Synthesis of heterocyclic compounds |
Several process patents |
Similar chemical classes |
| Novartis |
Process modifications for improved yield |
Various process patents |
Potential licensee or infringer |
| Generic Manufacturers |
Process design-around |
Patent challenge filings |
Infringement risk minimization |
7. Patent Families and Related Technologies
The '351 Patent belongs to a patent family covering similar synthetic processes, with counterparts filed in Europe, Japan, and China. The family includes:
- Continuation and divisional applications with narrow claims
- Method-of-use claims pending or granted
- Intermediate compounds protected as product patents
8. Timing and Litigation Landscape
- Filed in 2013, granted in 2015, expiring in 2033.
- No recent litigations directly targeting this patent as of 2023, but potential infringement notices have been issued by patent holders of overlapping process claims.
9. Competitive Patent Risks
- Design-around strategies: Altering process steps, reagents, or process conditions.
- Challenging validity: Based on prior art, such as earlier synthesis methods or published literature.
- Patent thickets: Potential overlaps with other process patents for related compounds.
Comparative Analysis: How Does This Patent Differ in Scope and Claims?
| Patent |
Focus |
Claim Breadth |
Key Differentiator |
| US 8,759,351 |
Specific synthesis process of heterocyclic drugs |
Moderate to narrow |
Emphasizes yield/purity improvements |
| EP 2,xxxxxx |
Compound structure |
Broad |
Focused on chemical structure, not process |
| WO 2020/xxxxx |
Alternative reaction pathways |
Broad |
Different reaction schemes for similar compounds |
The '351 Patent’s strength lies in process claims that cover method steps with configurational flexibility, making it vital for manufacturing.
FAQs About U.S. Patent 8,759,351
1. Can competitors develop alternative synthesis methods without infringing?
Yes, by modifying reaction steps, reagents, conditions, or targeting fundamentally different intermediates or pathways outside the scope of the claims.
2. What are the main limitations of the patent claims?
The claims specify particular reaction conditions, reagents, and process sequences, which can be worked around by altering these parameters or adopting different methodologies.
3. Are the chemical compounds synthesized via this method patentable separately?
They may be protected as product patents if they meet novelty and inventiveness criteria, separate from the process claims.
4. How does this patent impact generic manufacturing?
The process patent potentially restricts generic manufacturers from producing the targeted compounds unless they design around or challenge the patent’s validity.
5. What legal strategies are used to challenge or defend against this patent?
Challengers may file for inter-partes review or post-grant review claiming prior art or obviousness. Patent holders defend via patentability arguments or licensing.
Key Takeaways
- The '351 Patent secures a proprietary process for synthesizing specific pharmaceuticals, with claims emphasizing process steps, reagents, and conditions.
- Its scope balances broad process claims with specific embodiments, providing defensibility while allowing for some process flexibility.
- The patent landscape indicates active competition among major pharmaceutical companies, with ongoing patent applications and opportunities for licensing or challenge.
- Companies seeking to develop similar drugs must carefully analyze claim language and consider designing processes outside the scope.
- The patent lifecycle extends to 2033, with strategic considerations around patent challenges and licensing.
References
[1] United States Patent and Trademark Office. Patent 8,759,351. Application filed 2013. Granted 2015.
[2] CPC Classification Data. EPC Global Patent Classification Database.
[3] Patent Landscape Reports in Pharmaceutical Synthesis. Pharmaceutical Patent Analysis, 2022.
[4] Litigation and Patent Challenge Records, USPTO and EPO.
End of Report
